Skip to main content

Aging clinical trials at UCSF

3 in progress, 2 open to eligible people

Aging is a natural process where our body and mind change over time. At UCSF, we're running clinical trials to study how to improve the quality of life for older adults. These trials include studying the effectiveness and safety of a new treatment for head and neck cancer, and a pilot program to improve sleep and cognitive health to reduce the risk of developing Alzheimer's disease. Joining these studies may provide access to new treatments and help advance medical research.

Showing trials for
  • Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease

    open to eligible people ages 65 years and up

    This study aimed to pilot test a non-pharmacological (behavioral) treatment program targeting improved cognition through improving 24-h sleep-wake cycle in people with mild cognitive impairment (MCI) or mild Alzheimer's disease. A treatment program incorporating bright light therapy and a modified cognitive behavioral therapy for insomnia will be developed to address 24-hour patterns of sleep. We will then pilot test its feasibility and explore its preliminary effects on improving sleep/napping and cognition in patients with MCI or mild Alzheimer's disease.

    San Francisco, California

  • NBTXR3 With or Without Cetuximab in LA-HNSCC

    open to eligible people ages 65 years and up

    This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy/performance and safety of NBTXR3/RT±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participants with LA-HNSCC.

    San Francisco, California and other locations

  • Methylglyoxal (MGO) Lowering Cocktail to Reduce Appetite in Obese Individuals

    Sorry, not yet accepting patients

    Mechanisms that drive addiction to sugar rich foods are a major driving factor in the pathogenesis of obesity, which has become one of the most significant health care burdens. The molecular underpinnings of these hedonic mechanisms that drive addiction to sugar are poorly understood. The investigators demonstrated that methylglyoxal (MGO) derived Advanced Glycation Endproducts (AGEs) enhance food intake especially under a high sugar diet. The investigators identified a methylglyoxal (MGO) lowering cocktail, Gly-low, a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine that demonstrates a multimodal effect influencing many pathways related to aging including calorie restriction. Glycation lowering (Gly-low) treatment significantly reduces food intake and weight gain in the db/db mice that lack the leptin receptor. The investigators also extended the lifespan of C57BL/6 mice fed with these compounds starting when they were 24 months old. Based on these results, the investigators hypothesized that methylglyoxal (MGO) lowering cocktail of compounds can be given to adults with obesity, specified as body mass index (BMI) >27, to lower serum and urinary markers of insulin resistance, lower boy mass index (BMI), and lower food intake.

    San Francisco, California

Our lead scientists for Aging research studies include .

Last updated: